The Next Agonist
The pill under review is not the tan
The short answer, for anyone who searched the name hoping for a tan: dersimelagon is not Melanotan, and it is not for sale as one. It is an investigational oral drug for two rare diseases in which sunlight causes severe pain. The FDA has not approved it. A decision is due by the end of February 2027. Nothing on this page is a product you can order.
What is actually in front of the FDA
On 18 September 2026, LEO Pharma said the U.S. Food and Drug Administration had accepted a New Drug Application for dersimelagon and granted it priority review, with a Prescription Drug User Fee Act action date by the end of February 2027. The same announcement said LEO had closed its acquisition of worldwide rights from Tanabe Pharma, the company that ran the development program. Dersimelagon has not been approved by the FDA or any other regulator. The company’s own release says its safety and efficacy have not been established by any authority. (LEO Pharma, 18 September 2026.)
What the filing describes is narrow, and the narrowness is the point. Dersimelagon (also called MT-7117) is a once-daily oral small molecule that agonises the melanocortin-1 receptor — the same receptor at the centre of how a tan is signalled. The proposed use is erythropoietic protoporphyria and X-linked protoporphyria, the rare genetic disorders in which light causes severe pain. If it is approved, it would be the first oral treatment for those two diseases. It would not be a tanning pill for healthy people.
What the trial showed, and what it has not published
The application rests on INSPIRE, a global, randomised, double-blind, placebo-controlled Phase 3 study run by Tanabe before the sale. LEO said the study showed statistically significant and clinically meaningful results on primary and secondary endpoints, including a longer average daily time in sunlight before the first warning symptoms of a phototoxic reaction.
Read the next sentence as carefully as that one. The September filing announcement did not publish effect sizes, confidence intervals, or a detailed safety table. Dermatology Times noted the absence the day of the release. (Dermatology Times, 18 September 2026.) A sponsor saying an endpoint was met is not the same thing as a public dataset. This page will not invent the numbers the sponsor withheld.
The regulatory file records an earlier sponsor announcement, in January 2026, that INSPIRE enrolled 165 patients and met its primary endpoint. That figure lives there, dated, until a journal paper or an FDA review document replaces it. It is not repeated here as if the September release had confirmed it.
What a February decision would settle
A priority-review date is a clock, not a verdict. By the end of February 2027 the FDA can approve the application, issue a complete response, or extend the clock. Any of those is news. None of them turns dersimelagon into the cosmetic the gray market has been selling for eighteen years.
The pattern is the one this thread keeps finding. Oral delivery is the breakthrough the middle-ground file named as missing: a pill, not a clinic implant. The indication is the same beachhead afamelanotide already occupies — rare light-pain, not sun damage prevented in the general public. The class snapshot is where that comparison lives. This page is the query those essays were not titled to answer.
The future-agonist hope — a tested medicine that protects ordinary skin from ultraviolet damage — is this site’s labeled opinion, not a claim about dersimelagon. The drug in front of the FDA is a rare-disease filing. Anyone selling a tanning peptide under a name that sounds like it is still the cautionary tale.
This file will be updated when the agency acts, and only then. Freshness is not a date we restamp to look current.
Common questions
What is dersimelagon?
Dersimelagon (MT-7117) is an investigational, once-daily oral small-molecule agonist of the melanocortin-1 receptor. It is under FDA priority review for two rare genetic light-pain disorders, erythropoietic protoporphyria and X-linked protoporphyria. It is not approved anywhere, and it is not a tanning product.
When is the FDA decision on dersimelagon?
LEO Pharma said on 18 September 2026 that the FDA accepted the New Drug Application and granted priority review, with a PDUFA action date by the end of February 2027. That is a deadline for a decision, not a decision. This page will be updated when the agency actually acts.
Is dersimelagon the same as Melanotan?
No. Dersimelagon is a selective oral MC1R agonist in a regulated filing for two rare diseases. Melanotan II is an unapproved peptide sold for cosmetic tanning, with no trial, no label, and no manufacturer accountability. A pill in front of the FDA is not a vial on a website.